Investigational drugs reduce risk of death from Ebola virus disease
(NIH/National Institute of Allergy and Infectious Diseases) The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.
Two Ebola virus disease therapies, REGN-EB3 and mAb114, were so effective in a clinical trial that the trial was stopped, according to the National Institute of Allergy and Infectious Diseases (NIAID), which cosponsored the trial.
Health workers inside a "CUBE" talk to an Ebola patient, while a nurse consults a chart outside. ALIMA Ebola Treatment Centre, Beni, Democratic Republic of the Congo. Two drugs have been found to successfully treat the Ebola virus. Aid agencies have welcomed the news saying it allows communities to access early treatment. Courtesy: World Health Organisation (WHO)By Issa Sikiti da SilvaCOTONOU, Benin, Aug 20 2019 (IPS) While people in the Democratic Republic of Congo (DRC) are slowly being made aware that scientists have discovered two drugs that are effective in treating Ebola, letting go of the fear and anxiety ...
A year into an Ebola outbreak in the Democratic Republic of the Congo (DRC), researchers have halted an experimental drug trial there because early results appear so promising. The drugs will be made available to more patients in the DRC, hopefully saving lives as the current outbreak continues. But the decision to end the trial early has implications that go beyond the DRC: it could also change the way infectious disease treatments are studied in years to come. The trial, which began last November and enrolled 681 patients at four sites in the DRC, was meant to test four experimental Ebola therapies: ZMapp (an antibody co...
The therapies saved roughly 90 percent of the patients who were newly infected, a turning point in the decades-long fight against the virus.
The therapies saved roughly 90 percent of the patients who received them early in the course of infection. Doctors hope patients will seek out the cures, ending the outbreak.
Congo results show good survival rates for patients treated quickly with antibodiesEbola can no longer be called an incurable disease, scientists have said, after two of four drugs being trialled in themajor outbreak in the Democratic Republic of the Congo were found to have significantly reduced the death rate.ZMapp, used during the massive Ebola epidemic in Sierra Leone, Liberia and Guinea, has been dropped along with Remdesivir after two monoclonal antibodies, which block the virus, had substantially more effect, said the World Health Organization and the US National Institute of Allergy and Infectious Diseases, which w...
Condition: Ebola Virus Intervention: Biological: cAd3-EBO S vaccine Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); US Military HIV Research Program Recruiting
The human B-cell response to Ebola virus evolves significantly during the three years after infection, according to detailed studies of four survivors of the 2014 West African outbreak.Reuters Health Information